Single Source: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional)

The National Institutes of Health, under the U.S. Department of Health and Human Services, has announced a forecasted funding opportunity titled Single Source: HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Data Translation Center (U54 Clinical Trial Optional). This program is administered through the National Heart, Lung, and Blood Institute (NHLBI) and continues the agency’s long-standing commitment to cardiovascular research. The assistance listing number for this program is 93.837, which specifically supports cardiovascular disease research. The award will take the form of a cooperative agreement, reflecting the collaborative structure between NIH and the selected awardee. The purpose of this notice is to provide advanced information on the forthcoming opportunity and to give sufficient time for potential applicants to prepare. The NHLBI intends to fund a single application for the renewal of the Data Translation Center (DTC) within the HeartShare program. The DTC plays a central role in refining the classification of heart failure with preserved ejection fraction (HFpEF), analyzing data from existing NIH cohorts and trials, and coordinating with other centers that form part of the larger HeartShare initiative. The work of the DTC will include supporting patient cohorts, curating extensive datasets, and generating insights to guide the development of personalized clinical trials for patients with heart failure. Funding under this initiative will specifically support the continuation of HeartShare 2.0, which is designed to advance the NHLBI’s broader mission of addressing the complexity of heart failure. Through this effort, the DTC will provide infrastructure and data resources to ensure that the companion Clinical Trial Center and up to seven Clinical Centers, solicited through related funding opportunities, have coordinated access to data and analysis pipelines. By doing so, the program aims to identify new treatment targets and refine patient subtypes, ultimately leading to improved trial design and clinical outcomes. The eligibility for this funding opportunity is extremely limited. Only Northwestern University is eligible to apply, making this a non-competitive single source opportunity. The award is contingent upon the submission of a meritorious peer-reviewed application. This structure reflects the fact that Northwestern University has been centrally involved in the ongoing HeartShare program, ensuring continuity in leadership, data management, and scientific expertise. While public and state-controlled institutions of higher education are listed as eligible applicants more generally, the notice clarifies that Northwestern University alone is eligible under this particular single source award. The estimated timeline for this program begins with an anticipated post date of October 15, 2025. Applications will be due by December 15, 2025, and successful applicants are expected to be notified of awards by May 1, 2026. The project start date is projected to be July 1, 2026. At present, no funding ceiling, floor, or total program amount has been disclosed, and applicants are advised that this information may be forthcoming in the official Notice of Funding Opportunity. This is a forecast notice only, and no applications are currently being solicited. The point of contact for this grant is the Division of Cardiovascular Sciences, HeartShare Team at the National Heart, Lung, and Blood Institute. Interested parties are instructed to contact the team via email. No telephone number was provided in the source notice. Applications will be subject to the standard peer review process and must be submitted through Grants.gov when the official announcement is posted. Applicants are reminded that this program will use the U54 cooperative agreement activity code. The authorities for this funding mechanism are drawn from Sections 301 and 405 of the Public Health Service Act, as amended, and related federal regulations.